UFT/leucovorin and mitomycin C as salvage treatment in patients with advanced colorectal cancer - a retrospective analysis.

摘要: Active anticancer drugs and/or combination regimens for the treatment of patients failing oxaliplatin, irinotecan and 5-fluorouracil are desperately needed. In this analysis we describe safety efficacy mitomycin C, UFT leucovorin in such an extensively pretreated patient population. Between January 2002 June 2004, a total 41 were treated with C (8 mg/m 2 on day 1) (350 ) + (90 mg) both divided into three daily doses from 1 to 14 every 4 weeks. All had failed prior first-line second-line 5-fluorouracil. The aim retrospective was evaluate data potential salvage therapy regimen. Thirty-nine evaluable response. overall response rate (intent-to-treat) 7.3% (95% confidence interval, 2.5-19.4%) disease stabilization achieved 29.3%. Median time progression 2.5 months (range, 1.5-13.5) median survival 6 1.5-26). Myelosuppression most frequent side effect. Grade 3 hematotoxicity, however, observed only patients. common nonhematological toxicities consisted mild reversible nausea, emesis diarrhea; again, severe symptoms occasionally seen. These show that C/UFT/leucovorin is safe active about one-third terms abrogation metastatic colorectal cancer.